{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:16:14Z","timestamp":1789503374617,"version":"build-2803163510"},"reference-count":38,"publisher":"American Diabetes Association","issue":"7","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":281,"URL":"http:\/\/www.diabetesjournals.org\/site\/license"}],"funder":[{"DOI":"10.13039\/100008985","name":"Diab\u00e8te Qu\u00e9bec","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008985","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Canadian Heads of Academic Radiology-GE Healthcare"},{"name":"NSERC Discovery","award":["107998"],"award-info":[{"award-number":["107998"]}]},{"name":"Fonds de recherche du Qu\u00e9bec en Sant\u00e9 (FRQ-S) and Fondation de l'association des radiologistes du Qu\u00e9bec. Clinical Research Scholarship to An Tang","award":["#26993"],"award-info":[{"award-number":["#26993"]}]},{"name":"J-A DeS\u00e8ve Research Chair to R\u00e9mi Rabasa-Lhoret"},{"name":"FRQ-S National Scientist Award to Gilles Soulez"},{"name":"FRQ-S Senior Scholarship to R\u00e9mi Rabasa-Lhoret"},{"name":"Canada Research Chair in 3D imaging and Biomedical Engineering to Jacques de Guise"},{"name":"Radiological Society of North America Research and Education Foundation","award":["RSD1108"],"award-info":[{"award-number":["RSD1108"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>This study determined the effects of insulin versus liraglutide therapy on liver fat in patients with type 2 diabetes inadequately controlled with oral agents therapy, including metformin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Thirty-five patients with type 2 diabetes inadequately controlled on metformin monotherapy or in combination with other oral antidiabetic medications were randomized to receive insulin glargine or liraglutide therapy for 12 weeks. The liver proton density fat fraction (PDFF) was measured by MRS. The mean liver PDFF, the total liver volume, and the total liver fat index were measured by MRI. The Student t test, the Fisher exact test, and repeated-measures ANOVA were used for statistical analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Insulin treatment was associated with a significant improvement in glycated hemoglobin (7.9% to 7.2% [62.5 to 55.2 mmol\/mol], P = 0.005), a trend toward a decrease in MRS-PDFF (12.6% to 9.9%, P = 0.06), and a significant decrease in liver mean MRI-PDFF (13.8% to 10.6%, P = 0.005), liver volume (2,010.6 to 1,858.7 mL, P = 0.01), and the total liver fat index (304.4 vs. 209.3 % \u22c5 mL, P = 0.01). Liraglutide treatment was also associated with a significant improvement in glycated hemoglobin (7.6% to 6.7% [59.8 to 50.2 mmol\/mol], P &amp;lt; 0.001) but did not change MRS-PDFF (P = 0.80), liver mean MRI-PDFF (P = 0.15), liver volume (P = 0.30), or the total liver fat index (P = 0.39).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>The administration of insulin glargine therapy reduced the liver fat burden in patients with type 2 diabetes. However, the improvements in the liver fat fraction and glycemia control were not significantly different from those in the liraglutide group.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc14-2548","type":"journal-article","created":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T12:53:51Z","timestamp":1427460831000},"page":"1339-1346","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":124,"title":["Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial"],"prefix":"10.2337","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8967-5503","authenticated-orcid":false,"given":"An","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Radiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Rabasa-Lhoret","sequence":"additional","affiliation":[{"name":"Institut de Recherches Cliniques de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Medicine and Endocrinology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), H\u00f4pital Hotel-Dieu, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Castel","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Wartelle-Bladou","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), H\u00f4pital Notre-Dame, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"MR Clinical Science, Philips Healthcare Canada, Markham, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Massicotte-Tisluck","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Chartrand","sequence":"additional","affiliation":[{"name":"Imaging and Orthopaedics Research Laboratory (LIO), \u00c9cole de Technologie Sup\u00e9rieure, Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Olivi\u00e9","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Julien","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, Pavillon Andr\u00e9-Aisenstadt, Universit\u00e9 de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"de Guise","sequence":"additional","affiliation":[{"name":"Imaging and Orthopaedics Research Laboratory (LIO), \u00c9cole de Technologie Sup\u00e9rieure, Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Soulez","sequence":"additional","affiliation":[{"name":"Department of Radiology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Chiasson","sequence":"additional","affiliation":[{"name":"Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CRCHUM), Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Department of Medicine and Endocrinology, Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM), H\u00f4pital Hotel-Dieu, Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2015,3,26]]},"reference":[{"key":"2022031221224387400_B1","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.2337\/dc13-S011","article-title":"Standards of medical care in diabetes\u20142013","volume":"36","author":"American Diabetes Association","year":"2013","journal-title":"Diabetes Care"},{"key":"2022031221224387400_B2"},{"key":"2022031221224387400_B3"},{"key":"2022031221224387400_B4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1001\/jama.2014.5951","article-title":"Insulin therapy for type 2 diabetes mellitus","volume":"311","author":"Wallia","year":"2014","journal-title":"JAMA"},{"key":"2022031221224387400_B5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tem.2008.08.005","article-title":"Insulin resistance, inflammation, and non-alcoholic fatty liver disease","volume":"19","author":"Tilg","year":"2008","journal-title":"Trends Endocrinol Metab"},{"key":"2022031221224387400_B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jdiacomp.2007.02.005","article-title":"Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes","volume":"21","author":"Lingvay","year":"2007","journal-title":"J Diabetes Complications"},{"key":"2022031221224387400_B7","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1152\/ajpendo.00133.2006","article-title":"Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes","volume":"292","author":"Juurinen","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2022031221224387400_B8","doi-asserted-by":"crossref","first-page":"e50077","DOI":"10.1371\/journal.pone.0050077","article-title":"Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus","volume":"7","author":"Jankovic","year":"2012","journal-title":"PLoS ONE"},{"key":"2022031221224387400_B9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1463-1326.2011.01370.x","article-title":"Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes","volume":"13","author":"Shah","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"2022031221224387400_B10","doi-asserted-by":"crossref","first-page":"G225","DOI":"10.1152\/ajpgi.00274.2011","article-title":"Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL\/6J mice fed a Western diet","volume":"302","author":"Mells","year":"2012","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022031221224387400_B11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2022031221224387400_B12","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver Int"},{"key":"2022031221224387400_B13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"key":"2022031221224387400_B14"},{"key":"2022031221224387400_B15","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jmri.22580","article-title":"Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy","volume":"34","author":"Reeder","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"2022031221224387400_B16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1148\/radiol.12120896","article-title":"Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis","volume":"267","author":"Tang","year":"2013","journal-title":"Radiology"},{"key":"2022031221224387400_B17","unstructured":"Centre hospitalier de l'Universit\u00e9 de Montr\u00e9al (CHUM); Universit\u00e9 de Montr\u00e9al. Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 Diabetes (LIRAINS). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2000. Available from http:\/\/clinicaltrials.gov\/show\/NCT01399645 NLM Identifier: NCT01399645. Accessed 15 December 2014"},{"key":"2022031221224387400_B18","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2022031221224387400_B19","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.2337\/diabetes.51.10.3025","article-title":"Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle","volume":"51","author":"Anderwald","year":"2002","journal-title":"Diabetes"},{"key":"2022031221224387400_B20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"2022031221224387400_B21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1006\/jmre.1997.1244","article-title":"Improved method for accurate and efficient quantification of MRS data with use of prior knowledge","volume":"129","author":"Vanhamme","year":"1997","journal-title":"J Magn Reson"},{"key":"2022031221224387400_B22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/nbm.1622","article-title":"In vivo characterization of the liver fat \u00b9H MR spectrum","volume":"24","author":"Hamilton","year":"2011","journal-title":"NMR Biomed"},{"key":"2022031221224387400_B23","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1148\/radiol.10100659","article-title":"Estimation of hepatic proton-density fat fraction by using MR imaging at 3.0 T","volume":"258","author":"Yokoo","year":"2011","journal-title":"Radiology"},{"key":"2022031221224387400_B24","article-title":"Cross-sectional and longitudinal evaluation of liver volume and total liver fat burden in adults with nonalcoholic steatohepatitis","author":"Tang","year":"2014","journal-title":"Abdom Imaging"},{"key":"2022031221224387400_B25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1148\/radiology.162.3.3809503","article-title":"Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after low-calorie diet","volume":"162","author":"Nomura","year":"1987","journal-title":"Radiology"},{"key":"2022031221224387400_B26","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1016\/j.transproceed.2008.08.045","article-title":"Correlation between hepatic steatosis, hepatic volume, and spleen volume in live liver donors","volume":"40","author":"Chen","year":"2008","journal-title":"Transplant Proc"},{"key":"2022031221224387400_B27","doi-asserted-by":"crossref","first-page":"e25269","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"key":"2022031221224387400_B28","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1210\/en.2012-1165","article-title":"Effects of liraglutide on \u03b2-cell-specific glucokinase-deficient neonatal mice","volume":"153","author":"Shirakawa","year":"2012","journal-title":"Endocrinology"},{"key":"2022031221224387400_B29","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1038\/ajg.2010.363","article-title":"Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series","volume":"105","author":"Kenny","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"2022031221224387400_B30","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"Cuthbertson","year":"2012","journal-title":"PLoS One"},{"key":"2022031221224387400_B31","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2169\/internalmedicine.52.8961","article-title":"Effects of liraglutide, a human glucagon-like peptide-1 analogue, on body weight, body fat area and body fat-related markers in patients with type 2 diabetes mellitus","volume":"52","author":"Suzuki","year":"2013","journal-title":"Intern Med"},{"key":"2022031221224387400_B32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"2022031221224387400_B33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1203858","article-title":"Basal insulin and cardiovascular and other outcomes in dysglycemia","volume":"367","author":"Gerstein","year":"2012","journal-title":"N Engl J Med"},{"key":"2022031221224387400_B34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1148\/radiol.13121631","article-title":"Exercise and type 2 diabetes mellitus: changes in tissue-specific fat distribution and cardiac function","volume":"269","author":"Jonker","year":"2013","journal-title":"Radiology"},{"key":"2022031221224387400_B35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/dmrr.1305","article-title":"Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis","volume":"28","author":"Chaudhuri","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"key":"2022031221224387400_B36","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3109\/00365521.2011.558112","article-title":"Percutaneous liver biopsy: patients\u2019 point of view","volume":"46","author":"Fern\u00e1ndez-Salazar","year":"2011","journal-title":"Scand J Gastroenterol"},{"key":"2022031221224387400_B37","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"2022031221224387400_B38","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/7\/1339\/624592\/dc142548.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/38\/7\/1339\/624592\/dc142548.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T23:36:20Z","timestamp":1647128180000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/38\/7\/1339\/30868\/Effects-of-Insulin-Glargine-and-Liraglutide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,26]]},"references-count":38,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2015,3,26]]},"published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc14-2548","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,26]]}}}